(59 days)
Not Found
Not Found
No
The summary describes a mechanical device (sphincterotome) and does not mention any AI/ML terms, image processing, or data-driven performance metrics.
Yes.
The device is used for transendoscopic sphincterotomy, which is a therapeutic procedure to incise the Papilla of Vater and/or the Sphincter of Oddi.
No
The device is indicated for therapeutic procedures (sphincterotomy), not for diagnosing a condition. While it can be used to inject contrast, which can aid in imaging for diagnosis, its primary described use is an intervention.
No
The description clearly indicates a physical device, a "Needle Knife Sphincterotome," used for surgical procedures, not a software-only application.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use describes a surgical procedure (sphincterotomy) and a diagnostic imaging procedure (cannulation and contrast injection). These are performed directly on the patient's body.
- IVD Definition: In Vitro Diagnostics are devices used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening. The Microvasive Needle Knife Sphincterotome does not process such specimens.
- Lack of IVD Characteristics: The description doesn't mention any components or processes related to analyzing biological samples.
Therefore, the Microvasive Needle Knife Sphincterotome is a surgical and diagnostic device used in vivo (within the living body), not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Microvasive® Needle Knife Sphincterotome is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. The Microvasive Needle Knife can also be used to cannulate and inject contrast medium.
Product codes
78 KNS
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Papilla of Vater and/or the Sphincter of Oddi
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Laboratory testing regarding characteristics was performed on the Microvasive® Needle Knife Sphincterotome to verify its safety and performance. A biocompatibility assessment was performed on the patient- and fluid-contact materials of the Microvasive® Needle Knife Sphincterotome with satisfactory results.
Key Metrics
Not Found
Predicate Device(s)
Microvasive® Rapid Exchange Sphincterotome, Ultratome XLTM Triple Lumen Sphincterotome
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.4300 Endoscopic electrosurgical unit and accessories.
(a)
Identification. An endoscopic electrosurgical unit and accessories is a device used to perform electrosurgical procedures through an endoscope. This generic type of device includes the electrosurgical generator, patient plate, electric biopsy forceps, electrode, flexible snare, electrosurgical alarm system, electrosurgical power supply unit, electrical clamp, self-opening rigid snare, flexible suction coagulator electrode, patient return wristlet, contact jelly, adaptor to the cord for transurethral surgical instruments, the electric cord for transurethral surgical instruments, and the transurethral desiccator.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows handwritten text that appears to be a combination of letters and numbers. The first line reads 'K973826', and the second line reads '1 of 2'. The handwriting is somewhat rough, giving the text a casual and informal appearance.
SECTION 9 510(K) SUMMARY
DEC - 5 1997
FOI RELEASABLE
Pursuant to §513(i)(3)(A) of the Food, Drug, and Cosmetic Act, Boston Scientific Corporation is required to submit with this Premarket Notification "...adequate summary of any information respecting safety and effectiveness or state that such information will be made available upon request of any person." Boston Scientific Corporation chooses to submit a summary of information respecting safety and effectiveness.
| ➤ COMMON/USUAL NAMES: | Sphincterotome | ||
|---|---|---|---|
| ➤ TRADE/PROPRIETARY NAME: | None at this time | ||
| ➤ CLASSIFICATION NAME & | |||
| DEVICE CLASSIFICATION: | Class II | ||
| Name | Number | 21 CFR Ref | |
| Endoscopic Electrosurgical | |||
| Unit and Accessories. | 78 KNS | 876.4300 | |
| ➤ DEVICE PANEL/BRANCH: | Gastroenterology-Urology (GU) | ||
| Gastro-Renal (GRDB) | |||
| ➤ OWNER/OPERATOR: | Boston Scientific Corporation | ||
| One Boston Scientific Place | |||
| Natick, MA 01760 | |||
| ➤ CONTACT PERSON: | Daniel J. Dillon, Senior Regulatory Affairs Specialist |
INDICATIONS FOR USE
The Microvasive® Needle Knife Sphincterotome is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi.
Contraindications
Contraindications for this device are those specific to endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES).
1
COMPLICATIONS
Possible complications include, but may not be limited to: pancreatitis; perforation; hemorrhage, hematoma, cholangitis; stone impaction; septicemia/infection; and allergic reaction to contrast medium
SUBSTANTIAL EQUIVALENCE
Boston Scientific Corporation believes that the Microvasive® Needle Knife Sphincterotome is substantially .equivalent to the currently-marketed Microvasive® Rapid Exchange Sphincterotome and Ultratome XLTM Triple Lumen Sphincterotome.
Performance Characteristics
Laboratory testing regarding characteristics was performed on the Microvasive® Needle Knife Sphincterotome to verify its safety and performance. A biocompatibility assessment was performed on the patient- and fluid-contact materials of the Microvasive® Needle Knife Sphincterotome with satisfactory results.
Packaging, Sterilization, And Pyrogenicity
The Microvasive® Needle Knife Sphincterotome will be sterile in a tray sealed with a Tyvek lid. The Microvasive® Needle Knife Sphincterotome will be sterilized using ethylene oxide gas using the AAMI protocol for ethylene oxide sterilization. Pyrogenicity testing will be performed on a periodic basis to monitor bacterial endotoxin levels.
CONCLUSION
Boston Scientific Corporation believes that Microvasive® Needle Knife Sphincterotome is substantially equivalent to the currently-marketed Microvasive® Rapid Exchange Sphincterotome and Ultratome XLTM Triple Lumen Sphincterotome. A comparison of the descriptive characteristics of these products demonstrate the Microvasive® Needle Knife Sphincterotome is equivalent in its indications for use, while being very similar in design and materials. In addition, Boston Scientific Corporation has presented laboratory testing and biocompatibility information. The information presented provides assurance that the Microvasive® Needle Knife Sphincterotome will meet the minimum requirements that are considered acceptable for its intended use.
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular emblem with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing right, stacked on top of each other.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC - 5 1997
Mr. Daniel J. Dillon Senior Regulatory Affairs Specialist Boston Scientific Corporation One Boston Scientific Place Natick, Massachusetts 01760-1537
Re: K973826 Microvasive® Needle Knife Sphincterotome Dated: October 3, 1997 Received: October 7, 1997 Regulatory class: II 21 CFR §876.4300/Product code 78 KNS
Dear Mr. Dillon:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus. permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807,97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours.
h. William Yu
Lillian Yin, Ph.D. Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
3
510(k) Number:
Fo Be Determined K973826
Device Name:
Microvasive® Needle Knife Sphincterotome
Indication for Use:
The Microvasive® Needle Knife Sphincterotome is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. The Microvasive Needle Knife can also be used to cannulate and inject contrast medium.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Robert R. Satting/
(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use_